STRIP2

Summary

STRIP2 (striatin interacting protein 2, HGNC:22209) is a protein-coding gene on chromosome 7q32.1, encoding Striatin-interacting protein 2 (Q9ULQ0). Plays a role in the regulation of cell morphology and cytoskeletal organization.

Involved in cell migration; cytoskeleton organization; and regulation of cell shape. Located in cytosol. Part of FAR/SIN/STRIPAK complex.

Source: NCBI Gene 57464 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Tourette syndrome (No Known Disease Relationship, GenCC)
• Clinical variants (ClinVar): 110 total — 1 pathogenic
• MANE Select transcript: NM_020704

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:22209
Approved symbol	STRIP2
Name	striatin interacting protein 2
Location	7q32.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1170, FAR11B
Ensembl gene	ENSG00000128578
Ensembl biotype	protein_coding
OMIM	617919
Entrez	57464

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 retained_intron

ENST00000249344, ENST00000435494, ENST00000465033, ENST00000889796, ENST00000947594

RefSeq mRNA: 2 — MANE Select: NM_020704 NM_001134336, NM_020704

CCDS: CCDS34752, CCDS47709

Canonical transcript exons

ENST00000249344 — 21 exons

Exon	Start	End
ENSE00000722828	129453227	129453347
ENSE00000722830	129454142	129454210
ENSE00000722832	129454421	129454527
ENSE00000722835	129455244	129455371
ENSE00000882353	129440022	129440091
ENSE00000882354	129444024	129444098
ENSE00000882355	129451613	129451747
ENSE00000882356	129456439	129456642
ENSE00000882357	129458215	129458450
ENSE00000882359	129460301	129460372
ENSE00001207264	129485579	129488399
ENSE00001712110	129434432	129434601
ENSE00002437309	129480785	129480889
ENSE00002455807	129467350	129467450
ENSE00002490470	129464612	129464738
ENSE00002502386	129482842	129483046
ENSE00002503875	129470649	129470715
ENSE00002513797	129462966	129463040
ENSE00002518586	129464044	129464141
ENSE00003544470	129459517	129459580
ENSE00003584822	129458712	129458777

Expression profiles

Bgee: expression breadth ubiquitous, 208 present calls, max score 95.11.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.6769 / max 282.4853, expressed in 1291 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
81034	8.5017	1282
81033	0.1752	69

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pigmented layer of retina	UBERON:0001782	95.11	gold quality
vastus lateralis	UBERON:0001379	92.65	gold quality
quadriceps femoris	UBERON:0001377	92.52	gold quality
tibialis anterior	UBERON:0001385	91.70	gold quality
lateral globus pallidus	UBERON:0002476	91.38	gold quality
deltoid	UBERON:0001476	91.11	gold quality
caudate nucleus	UBERON:0001873	90.99	gold quality
skeletal muscle tissue	UBERON:0001134	90.84	gold quality
nucleus accumbens	UBERON:0001882	90.70	gold quality
putamen	UBERON:0001874	90.56	gold quality
biceps brachii	UBERON:0001507	90.24	gold quality
gastrocnemius	UBERON:0001388	90.10	gold quality
right testis	UBERON:0004534	89.34	gold quality
left testis	UBERON:0004533	88.95	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	88.84	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	88.80	gold quality
muscle of leg	UBERON:0001383	88.76	gold quality
muscle tissue	UBERON:0002385	87.28	gold quality
cartilage tissue	UBERON:0002418	86.73	gold quality
heart right ventricle	UBERON:0002080	86.37	gold quality
testis	UBERON:0000473	86.17	gold quality
hindlimb stylopod muscle	UBERON:0004252	85.54	gold quality
left ventricle myocardium	UBERON:0006566	85.26	gold quality
myocardium	UBERON:0002349	83.35	silver quality
right hemisphere of cerebellum	UBERON:0014890	82.79	gold quality
heart left ventricle	UBERON:0002084	82.46	gold quality
cardiac ventricle	UBERON:0002082	82.36	gold quality
cerebellar hemisphere	UBERON:0002245	82.30	gold quality
cerebellar cortex	UBERON:0002129	82.24	gold quality
cerebellum	UBERON:0002037	81.55	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	326.89
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

41 targeting STRIP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-379-3P	99.69	69.60	1524
HSA-MIR-411-3P	99.69	69.63	1524
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-4666B	99.64	68.69	1282
HSA-MIR-1251-3P	99.64	67.21	1408
HSA-MIR-6832-5P	99.58	64.82	1132
HSA-MIR-888-3P	99.53	69.77	1057
HSA-MIR-409-3P	99.50	66.33	1192
HSA-MIR-203A-3P	99.49	70.56	2806
HSA-MIR-12131	99.48	68.72	1673
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-3978	99.24	68.39	2201
HSA-MIR-2054	99.20	68.89	1699
HSA-MIR-4426	99.17	66.74	1949
HSA-MIR-452-3P	99.01	66.25	1241

Literature-anchored findings (GeneRIF, showing 6)

• this study propose that the STRIPAK complex, FAM40A, FAM40B and STRN3, regulates the mode of cancer cell migration by controlling the activity of MST3 and 4, which locally coordinate the phosphorylation of ERM proteins and inhibit the dephosphorylation of MLC leading to increased actin-membrane linkage. (PMID:25531779)
• Data indicate that a cardiac protein named Myoscape/FAM40B/STRIP2, which directly interacts with the L-type calcium channel CaV1.2. (PMID:27122098)
• These results demonstrate the importance of the FAM40 proteins for endothelial cell physiology, and suggest that they act as part of the CCM3-containing STRIPAK complex. (PMID:30509168)
• STRIP2, a member of the striatin-interacting phosphatase and kinase complex, is implicated in lung adenocarcinoma cell growth and migration. (PMID:31901223)
• STRIP2 motivates non-small cell lung cancer progression by modulating the TMBIM6 stability through IGF2BP3 dependent. (PMID:36639675)
• STRIP2 is regulated by the transcription factor Sp1 and promotes lung adenocarcinoma progression via activating the PI3K/AKT/mTOR/MYC signaling pathway. (PMID:39191354)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	strip2	ENSDARG00000059003
mus_musculus	Strip2	ENSMUSG00000039629
rattus_norvegicus	Strip2	ENSRNOG00000057729
drosophila_melanogaster	Strip	FBGN0035437
caenorhabditis_elegans		WBGENE00017349

Paralogs (1): STRIP1 (ENSG00000143093)

Protein

Protein identifiers

Striatin-interacting protein 2 — Q9ULQ0 (reviewed: Q9ULQ0)

Alternative names: Protein FAM40B

All UniProt accessions (1): Q9ULQ0

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in the regulation of cell morphology and cytoskeletal organization. Required in the control of cell shape. Calmodulin-binding scaffolding protein which is the center of the striatin-interacting phosphatase and kinase (STRIPAK) complexes. STRIPAK complexes have critical roles in protein (de)phosphorylation and are regulators of multiple signaling pathways including Hippo, MAPK, nuclear receptor and cytoskeleton remodeling. Different types of STRIPAK complexes are involved in a variety of biological processes such as cell growth, differentiation, apoptosis, metabolism and immune regulation.

Subunit / interactions. Part of the core of STRIPAK complexes composed of PP2A catalytic and scaffolding subunits, the striatins (PP2A regulatory subunits), the striatin-associated proteins MOB4, STRIP1 and STRIP2, PDCD10 and members of the STE20 kinases, such as STK24 and STK26. Interacts with CTTNBP2NL.

Subcellular location. Cytoplasm.

Similarity. Belongs to the STRIP family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9ULQ0-1	1	yes
Q9ULQ0-2	2

RefSeq proteins (2): NP_001127808, NP_065755* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR012486	Far11/STRP_N	Domain
IPR021819	Far11/STRP_C	Domain
IPR040185	Far11/STRP	Family

Pfam: PF07923, PF11882

UniProt features (13 total): region of interest 3, compositionally biased region 3, modified residue 3, splice variant 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9ULQ0-F1	79.68	0.51

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 318, 329, 354

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (3): cytoskeleton organization (GO:0007010), regulation of cell shape (GO:0008360), cell migration (GO:0016477)

GO Molecular Function (0):

GO Cellular Component (3): cytoplasm (GO:0005737), cytosol (GO:0005829), FAR/SIN/STRIPAK complex (GO:0090443)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
organelle organization	1
regulation of cell morphogenesis	1
regulation of biological quality	1
cell motility	1
intracellular anatomical structure	1
cytoplasm	1
protein-containing complex	1

Protein interactions and networks

STRING

500 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
STRIP2	MOB4	Q9Y3A3	981
STRIP2	STRN	O43815	975
STRIP2	PDCD10	Q9BUL8	942
STRIP2	PPP2CA	P05323	882
STRIP2	PPP2R1A	P30153	876
STRIP2	STK25	O00506	853
STRIP2	STRN3	Q13033	812
STRIP2	STRN4	Q9NRL3	804
STRIP2	SLMAP	Q14BN4	801
STRIP2	STK26	Q9P289	799
STRIP2	SIKE1	Q9BRV8	782
STRIP2	STK24	Q9Y6E0	767
STRIP2	CTTNBP2	Q8WZ74	669
STRIP2	STRIP1	Q5VSL9	649
STRIP2	CTTNBP2NL	Q9P2B4	612

IntAct

62 interactions, top by confidence:

A	B	Type	Score
STK25	STRN	psi-mi:“MI:0914”(association)	0.900
STK24	STK25	psi-mi:“MI:0914”(association)	0.890
PPP2R1A	STRN	psi-mi:“MI:0914”(association)	0.880
PPP2R1A	STRN	psi-mi:“MI:2364”(proximity)	0.880
STRN3	STK25	psi-mi:“MI:0914”(association)	0.880
CTTNBP2NL	STK25	psi-mi:“MI:0914”(association)	0.880
STRN3	STRN	psi-mi:“MI:0914”(association)	0.880
STK24	STRN	psi-mi:“MI:0914”(association)	0.870
STK26	STRN	psi-mi:“MI:0914”(association)	0.860
PRDM14	CBFA2T2	psi-mi:“MI:0914”(association)	0.860
STRIP1	STK25	psi-mi:“MI:0914”(association)	0.840
PPP2CB	STRN	psi-mi:“MI:0914”(association)	0.790
MOB4	STRN	psi-mi:“MI:0914”(association)	0.790
STK26	STK25	psi-mi:“MI:0914”(association)	0.790
SIKE1	SLMAP	psi-mi:“MI:0914”(association)	0.770
MOB4	STK25	psi-mi:“MI:0914”(association)	0.730
SIKE1	STRN	psi-mi:“MI:0914”(association)	0.730
DYNLL1	BLTP3B	psi-mi:“MI:0914”(association)	0.730
SLMAP	STRN	psi-mi:“MI:0914”(association)	0.710
PRDM14	CBFA2T2	psi-mi:“MI:0914”(association)	0.670
CTTNBP2	STK25	psi-mi:“MI:0914”(association)	0.640
DYNLL2	BLTP3B	psi-mi:“MI:0914”(association)	0.640

BioGRID (78): STRIP2 (Affinity Capture-MS), STRIP2 (Affinity Capture-MS), STRIP2 (Affinity Capture-MS), STRIP2 (Affinity Capture-MS), STRIP2 (Affinity Capture-MS), STRIP2 (Affinity Capture-MS), STRIP2 (Affinity Capture-MS), STRIP2 (Affinity Capture-MS), STRIP2 (Affinity Capture-MS), STRIP2 (Affinity Capture-MS), STRIP2 (Affinity Capture-MS), STRIP2 (Affinity Capture-MS), STRIP2 (Affinity Capture-MS), STRIP2 (Affinity Capture-MS), STRIP2 (Affinity Capture-MS)

ESM2 similar proteins: A0A4X1TB62, A4VCH4, G3V7Q0, O14795, O35841, O43237, O70585, P23116, P48553, Q0P5J8, Q14152, Q15542, Q1JU68, Q3TLI0, Q3UHE1, Q4R5P6, Q5R660, Q5R7S4, Q5R7U7, Q5RE09, Q5RE70, Q5VSL9, Q5XI83, Q658Y4, Q68E01, Q6IQ26, Q6PAL8, Q6PDL0, Q6TEP1, Q6WKZ8, Q7SYD9, Q7TPD0, Q8BIK4, Q8BWQ6, Q8C079, Q8C092, Q8C9H6, Q8CBY8, Q8IWV8, Q8K400

Diamond homologs: Q0P5J8, Q5R7S4, Q5VSL9, Q803T2, Q8C079, Q8C9H6, Q9GLZ5, Q9ULQ0, O13665, Q54IL2

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 44 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal	5	23.3×	8e-05
EML4 and NUDC in mitotic spindle formation	5	18.6×	9e-05
Resolution of Sister Chromatid Cohesion	5	17.3×	1e-04
RHO GTPases Activate Formins	5	15.5×	2e-04
Mitotic Prometaphase	5	13.8×	3e-04
Separation of Sister Chromatids	5	12.2×	4e-04

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of hippo signaling	7	129.3×	2e-11
protein autophosphorylation	5	19.1×	4e-04
protein phosphorylation	7	12.5×	2e-04
intracellular signal transduction	8	8.0×	4e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

110 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	98
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1527394	GRCh37/hg19 7q31.33-33(chr7:124103982-134693590)	Pathogenic

SpliceAI

3773 predictions. Top by Δscore:

Variant	Effect	Δscore
7:129434597:CAGAG:C	donor_loss	1.0000
7:129434598:AGAGG:A	donor_loss	1.0000
7:129434599:GAG:G	donor_gain	1.0000
7:129434600:AGG:A	donor_loss	1.0000
7:129434601:GGTG:G	donor_loss	1.0000
7:129434602:GT:G	donor_loss	1.0000
7:129434603:T:G	donor_loss	1.0000
7:129451611:A:AG	acceptor_gain	1.0000
7:129451612:G:GA	acceptor_gain	1.0000
7:129451612:GT:G	acceptor_gain	1.0000
7:129451744:CAAGG:C	donor_loss	1.0000
7:129451745:AAGGT:A	donor_loss	1.0000
7:129451746:AGGTG:A	donor_loss	1.0000
7:129451747:GGT:G	donor_loss	1.0000
7:129451748:G:C	donor_loss	1.0000
7:129451748:G:GG	donor_gain	1.0000
7:129451749:T:G	donor_loss	1.0000
7:129453340:GAAAT:G	donor_gain	1.0000
7:129453344:T:G	donor_gain	1.0000
7:129453344:T:TG	donor_gain	1.0000
7:129453346:GA:G	donor_gain	1.0000
7:129453348:G:GG	donor_gain	1.0000
7:129454136:T:TA	acceptor_gain	1.0000
7:129454137:G:A	acceptor_gain	1.0000
7:129454138:GCA:G	acceptor_loss	1.0000
7:129454139:CA:C	acceptor_loss	1.0000
7:129454140:A:AG	acceptor_gain	1.0000
7:129454140:A:C	acceptor_loss	1.0000
7:129454141:G:GA	acceptor_gain	1.0000
7:129454141:GCA:G	acceptor_gain	1.0000

AlphaMissense

5483 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:129458755:T:C	F440L	1.000
7:129458757:C:A	F440L	1.000
7:129458757:C:G	F440L	1.000
7:129459540:T:C	L455S	1.000
7:129482854:T:C	F688L	1.000
7:129482856:T:A	F688L	1.000
7:129482856:T:G	F688L	1.000
7:129482857:A:G	K689E	1.000
7:129482858:A:T	K689I	1.000
7:129482859:A:C	K689N	1.000
7:129482859:A:T	K689N	1.000
7:129482953:G:A	G721R	1.000
7:129482953:G:C	G721R	1.000
7:129482954:G:A	G721E	1.000
7:129482956:C:A	R722S	1.000
7:129482962:T:A	W724R	1.000
7:129482962:T:C	W724R	1.000
7:129482964:G:C	W724C	1.000
7:129482964:G:T	W724C	1.000
7:129482966:G:C	R725T	1.000
7:129482966:G:T	R725M	1.000
7:129482967:G:C	R725S	1.000
7:129482967:G:T	R725S	1.000
7:129483031:T:A	W747R	1.000
7:129483031:T:C	W747R	1.000
7:129483033:G:C	W747C	1.000
7:129483033:G:T	W747C	1.000
7:129485767:T:A	W815R	1.000
7:129485767:T:C	W815R	1.000
7:129485771:T:C	L816P	1.000

dbSNP variants (sampled 300 via entrez): RS1000001238 (7:129440456 T>A), RS1000014712 (7:129439361 T>A), RS1000119000 (7:129454689 G>A), RS1000195978 (7:129451062 A>G,T), RS1000222626 (7:129446619 A>G), RS1000284331 (7:129481633 C>T), RS1000347507 (7:129483124 C>G,T), RS1000437738 (7:129435498 A>G), RS1000451180 (7:129439007 T>C), RS1000525758 (7:129445381 G>C), RS1000558340 (7:129444921 C>T), RS1000570630 (7:129477106 G>A,T), RS1000608358 (7:129483903 G>A), RS1000682607 (7:129484993 C>T), RS1000683877 (7:129436697 A>G)

Disease associations

OMIM: gene MIM:617919 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Tourette syndrome	No Known Disease Relationship	Unknown

Mondo (1): Tourette syndrome (MONDO:0007661)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, decreases expression	3
Valproic Acid	affects cotreatment, decreases expression	3
bisphenol A	decreases expression, decreases methylation	2
Benzo(a)pyrene	decreases expression, increases expression	2
Tretinoin	decreases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	increases expression	1
incobotulinumtoxinA	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Sunitinib	decreases expression	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	affects methylation	1
Vehicle Emissions	increases abundance, increases expression	1
Demecolcine	decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects expression	1
Hydrogen Peroxide	affects expression	1
Methyl Methanesulfonate	increases expression	1
Oxygen	decreases expression	1
Silicon Dioxide	increases expression	1
Tetrachlorodibenzodioxin	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Triclosan	decreases expression	1

Clinical trials (associated diseases)

183 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	PHASE4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	PHASE4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	PHASE4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	PHASE4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	PHASE4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00004376	PHASE3	COMPLETED	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
NCT00206323	PHASE3	COMPLETED	A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT00206336	PHASE3	COMPLETED	An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
NCT00478842	PHASE3	COMPLETED	Pallidal Stimulation and Gilles de la Tourette Syndrome
NCT00681863	PHASE3	TERMINATED	Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
NCT01501695	PHASE3	COMPLETED	Phase III Study of 5LGr to Treat Tic Disorder
NCT03087201	PHASE3	COMPLETED	CANNAbinoids in the Treatment of TICS (CANNA-TICS)
NCT03487783	PHASE3	COMPLETED	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette’s Syndrome
NCT03567291	PHASE3	TERMINATED	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03571256	PHASE3	COMPLETED	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT06021522	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette’s Disorder
NCT00004393	PHASE2	COMPLETED	Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
NCT00004652	PHASE2	COMPLETED	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
NCT00231985	PHASE2	COMPLETED	Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
NCT00311909	PHASE2	COMPLETED	Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00529308	PHASE2	COMPLETED	Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette’s Syndrome
NCT00558467	PHASE2	COMPLETED	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT01043549	PHASE2	TERMINATED	Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
NCT01133353	PHASE2	WITHDRAWN	A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette’s Syndrome
NCT01475383	PHASE2	WITHDRAWN	Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette’s Syndrome
NCT01647269	PHASE2	COMPLETED	A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
NCT01904773	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder
NCT02102698	PHASE2	COMPLETED	Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years
NCT02217007	PHASE2	WITHDRAWN	A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02247206	PHASE2	COMPLETED	VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02581865	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02619084	PHASE2	COMPLETED	Subthalamic Stimulation in Tourette’s Syndrome
NCT02679079	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02879578	PHASE2	COMPLETED	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT03066193	PHASE2	COMPLETED	Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03247244	PHASE2	TERMINATED	Safety and Efficacy of Cannabis in Tourette Syndrome
NCT03325010	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038	PHASE2	COMPLETED	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome